3 active not recruiting, 3 not yet recruiting, 2 recruiting, 1 no longer available. 7 Phase 1, 3 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Active not recruiting 3, Not yet recruiting 2, Recruiting 2 |
| Phase 2 | 3 | Active not recruiting 2, Recruiting 1 |
| Early Phase 1 | 1 | Not yet recruiting 1 |
Follow KRAS G12V: new trials by email Literature Review of KRAS G12V trials Research Report on KRAS G12V
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1 Study of NW-301V TCR-T Cells in Advanced Solid Tumors With KRAS G12V Mutation Fludarabine, Cyclophosphamide, NW-301V - Advanced Solid Cancer, Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 | Not yet recruiting | Neowise Biotechnology | 66 | 2026-10-01 | 2026-10-15 |
| TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors TCR-T cells, Fludarabine, Cyclophosphamide - KRAS G12V, KRAS G12D | Early Phase 1 | Not yet recruiting | Sun Yat-sen University | 25 | 2026-02-01 | 2026-01-15 |
| BBO-11818 in Adult Subjects With KRAS Mutant Cancer BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin) - Non-Small Cell Lung Cancer, NSCLC | Phase 1 | Recruiting | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | 665 | 2025-03-31 | 2026-06-02 |
| RE001 T Cell Injection for the Treatment of KRAS G12V Mutated Solid Tumors RE001 T cell - KRAS G12V, T Cell Therapy | Phase 1 | Not yet recruiting | Henan Cancer Hospital | 30 | 2024-08-01 | 2024-08-09 |
| Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor AFNT-211 - Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Active not recruiting | Affini-T Therapeutics, Inc. | 100 | 2024-03-06 | 2025-07-30 |
| Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies S241656, FOLFOX6/FOLFOX7, FOLFIRI - Non-small Cell Lung Cancer, Histiocytic Neoplasm | Phase 1 / Phase 2 | Recruiting | Institut de Recherches Internationales Servier | 554 | 2023-04-18 | 2026-10-13 |
| A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors ELI-002 7P - Pancreatic Ductal Adenocarcinoma, Colorectal Cancer | Phase 1 / Phase 2 | Active not recruiting | Elicio Therapeutics | 158 | 2023-04-14 | 2026-07-10 |
| CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors KRAS-EphA-2-CAR-DC, Abraxane, Cyclophosphamide - Solid Tumor, Adult, EphA2 Overexpression | Phase 1 | Active not recruiting | Chinese PLA General Hospital | 9 | 2023-04-03 | 2025-11-24 |
| Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma ELI-002 7P - Pancreatic Ductal Adenocarcinoma, KRAS G12D | No longer available | Elicio Therapeutics | 2026-07-10 |
Colorectal Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (3) · Neoplasm Metastasis (2) · Adenocarcinoma of Lung (1) · Brain Neoplasms (1) · Colonic Neoplasms (1) · Histiocytosis (1) · Lung Neoplasms (1) · Pancreatic Neoplasms (1) · Rectal Neoplasms (1) · Syndactyly, Type I (1) · Thyroid Neoplasms (1)
Neoplasms (6) · Colonic Diseases (5) · Digestive System Diseases (5) · Digestive System Neoplasms (5) · Gastrointestinal Diseases (5) · Gastrointestinal Neoplasms (5) · Intestinal Diseases (5) · Intestinal Neoplasms (5) · Neoplasms by Site (5) · Rectal Diseases (5) · Respiratory Tract Neoplasms (4) · Thoracic Neoplasms (4) · Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Lung Diseases (3)
Cyclophosphamide (3) · 130-nm albumin-bound paclitaxel (2) · Cetuximab (2) · Gemcitabine (2) · fludarabine (2) · Albumin-Bound Paclitaxel (1) · Carboplatin (1) · Cisplatin (1) · IFL protocol (1) · Injections (1) · Ipilimumab (1) · Panitumumab (1) · Pemetrexed (1) · pembrolizumab (1) · spartalizumab (1)
Elicio Therapeutics (2) · Affini-T Therapeutics, Inc. (1) · Chinese PLA General Hospital (1) · Henan Cancer Hospital (1) · Institut de Recherches Internationales Servier (1) · Neowise Biotechnology (1) · Sun Yat-sen University (1) · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) (1)
China (5) · United States (4) · Australia (2) · Denmark (1) · France (1) · Hong Kong (1) · Italy (1) · Japan (1) · Spain (1) · United Kingdom (1)
Yang Xu, Ph.D (1)
2025 (1)